Project

The development of strong specific, efficient, flexible and safe TNF-receptor inhibitors for treatment of acute and chronic inflammatory diseases.

Code

3F021113

Duration

01 October 2013 → 23 October 2017

Funding

Regional and community funding: Special Research Fund, Research Foundation - Flanders (FWO)

Promotor

Claude Libert

Fellow

Sophie Steeland

Research disciplines

Medical and health sciences
- Biomarker discovery and evaluation
- Drug discovery and development
- Medicinal products
- Pharmaceutics
- Pharmacognosy and phytochemistry
- Pharmacology
- Pharmacotherapy
- Toxicology and toxinology
- Other pharmaceutical sciences

Keywords

TNFR1 nanobodies Inflammation

Project description

By developing of TNFR1 inhibitory Nanobodies, I will determine whether TNFR1 inhibition is a better approach than inhibition of TNF alone because those TNF-inhibitors have lots of side-effects which can be prevented by using selective TNFR1 inhibitors. We will determine the therapeutic nich of TNFR1 inhibition and due to the flexibility of Nanobody, targetsystems will be developed to target specific, inflammatory regions.